# EUROPAC

Source: https://onco.cc/trials/europac/  
OnCo record `europac` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The UK's registry and screening programme for families with inherited pancreatic cancer risk, run from Liverpool since 2000; its 2026 outcomes paper shows risk-stratified surveillance finds four times more actionable lesions.

## Summary

EUROPAC registers people with a family history of pancreatic cancer or with hereditary pancreatitis and offers imaging surveillance through its Europac-PRIME arm, with research on secondary screening through Europac-PLUS. The current ISRCTN record (62546421) lists the University of Liverpool as sponsor, recruitment from 1 July 2019 to 1 July 2039, a target of 10,000 and ten UK sites: Royal Liverpool, Glasgow Royal Infirmary, the Freeman in Newcastle, Leeds, Nottingham City, Morriston in Swansea, Bristol Royal Infirmary, Plymouth, Southampton and UCLH. The 2026 European Journal of Cancer outcomes paper reports that 893 asymptomatic individuals started surveillance between January 2000 and April 2025 (median age 52); after Family Risk stratification was introduced in 2020, actionable pancreatic findings rose from 0.8 percent (4 of 508) to 3.6 percent (14 of 385), and operable lesions from 0.6 to 3 percent. NICE NG85 recommends surveillance for hereditary pancreatitis with PRSS1, for BRCA1, BRCA2, PALB2 or CDKN2A carriers with a first-degree relative affected, and for Peutz-Jeghers syndrome; Pancreatic Cancer UK notes that EUROPAC is the route to it.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: European Registry of Familial Pancreatic Cancer and Hereditary Pancreatitis; Europac-PRIME; Europac-PLUS; ISRCTN62546421
- Tags: uk; surveillance; familial; pancreatic
- Registry id: ISRCTN62546421
- Phase: observational
- Setting: Registry and surveillance programme for people at inherited risk of pancreatic cancer (familial pancreatic cancer, hereditary pancreatitis, BRCA2, PALB2, CDKN2A and other predisposition variants) at ten UK sites; recruiting from July 2019 to July 2039 with a target of 10,000
- Sponsor: University of Liverpool
- Enrolled: 10000
- Result: Risk-stratified surveillance (2020 onwards) found actionable pancreatic lesions in 3.6 percent of participants against 0.8 percent before stratification (p = 0.001), and operable lesions in 3 percent against 0.6 percent (European Journal of Cancer 2026).

## Sources

- ISRCTN62546421: https://www.isrctn.com/ISRCTN62546421
- Outcomes paper, European Journal of Cancer 2026: https://europepmc.org/article/MED/41740463
- Protocol, BMJ Open 2025: https://europepmc.org/article/MED/40180412
- Pancreatic Cancer UK: family history: https://www.pancreaticcancer.org.uk/information-and-support/family-history-of-pancreatic-cancer/

## Connected records

- cancers: [Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors](https://onco.cc/cancers/ipmn-cystic-precursors/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [PALB2](https://onco.cc/targets/palb2/)
- institutions: [Bristol Haematology and Oncology Centre](https://onco.cc/institutions/bristol-haematology-oncology-centre/), [Derriford Hospital, University Hospitals Plymouth](https://onco.cc/institutions/derriford-plymouth/), [Glasgow Royal Infirmary](https://onco.cc/institutions/glasgow-royal-infirmary/), [Leeds Cancer Centre, St James's University Hospital](https://onco.cc/institutions/leeds-cancer-centre/), [Liverpool University Hospitals HPB centre (Aintree)](https://onco.cc/institutions/liverpool-hpb-centre/), [Morriston Hospital, Swansea](https://onco.cc/institutions/morriston-swansea/), [Newcastle Cancer Centre / Northern Centre for Cancer Care](https://onco.cc/institutions/newcastle-cancer-centre/), [Nottingham University Hospitals Cancer Centre (City Hospital)](https://onco.cc/institutions/nottingham-cancer-centre/), [Pancreatic Cancer UK](https://onco.cc/institutions/pancreatic-cancer-uk/), [University College London Hospitals / UCL Cancer Institute](https://onco.cc/institutions/uclh/), [University Hospital Southampton / Centre for Cancer Immunology](https://onco.cc/institutions/southampton-cancer/)
- people: [Bill Greenhalf](https://onco.cc/people/bill-greenhalf/), [Chris Halloran](https://onco.cc/people/chris-halloran/)
- terms: [CAPS: the Cancer of the Pancreas Screening consortium and its surveillance studies (CAPS1 to CAPS5)](https://onco.cc/terms/caps-consortium-pancreatic-screening/), [Familial pancreatic cancer and inherited risk (who qualifies for surveillance)](https://onco.cc/terms/familial-pancreatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/europac.json